The Phase III ExteNET trial demonstrated that the irreversible pan-HER2 tyrosine kinase inhibitor neratinib, inhibiting PI3K/Akt and MAPK signaling, favorably increased disease-free survival in early-stage HER2-positive breast cancer patients, post-trastuzumab treatment [78]. The gene discussed is AKT1; the disease is breast cancer.